CO5560589A2 - 6,7-dihidro-5h-pirazol[1,2-a]pirazol-1-onas que controlan citosinas inflamatorias - Google Patents

6,7-dihidro-5h-pirazol[1,2-a]pirazol-1-onas que controlan citosinas inflamatorias

Info

Publication number
CO5560589A2
CO5560589A2 CO04021424A CO04021424A CO5560589A2 CO 5560589 A2 CO5560589 A2 CO 5560589A2 CO 04021424 A CO04021424 A CO 04021424A CO 04021424 A CO04021424 A CO 04021424A CO 5560589 A2 CO5560589 A2 CO 5560589A2
Authority
CO
Colombia
Prior art keywords
substituted
unsubstituted
hydrogen
alkyl
subscript
Prior art date
Application number
CO04021424A
Other languages
English (en)
Inventor
Matthew John Laufersweile
Jane Far-Jine Djung
Michael George Natchus
Biswanath De
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5560589A2 publication Critical patent/CO5560589A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

1.- Un compuesto que incluye todas las formas enantioméricas y diasterioméricas y las sales farmacéuticamente aceptables de las mismas, el compuesto corresponde a la fórmula: caracterizada además porque R es: a) -O[CH2]kR3; o b) -NR4aR4b;R3 es alquilo C1-C4 sustituido o no sustituido, hidrocarbilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo o alquilenarilo sustituido o no sustituido, heteroarilo o alquilenheteroarilo sustituido o no sustituido; el subíndice k es de 0 a 5;R4a y R4b son independientemente: a) hidrógeno; o b) -[C(R5aR5b)]mR6;cada R5a y R5b son independientemente hidrógeno, -OR7, -N(R7)2, -CO2R7, -CON(R7)2; alquilo C1-C4 lineal, ramificado o cíclico, y mezclas de los mismos; R6 es hidrógeno, -OR7, -N(R7)2, -CO2R7, -CON(R7)2; alquilo C1-C4 sustituido o no substituido, aril heterociclo sustituido o no sustituido, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; R7 es hidrógeno, un catión hidrosoluble, alquilo C1-C4 arilo sustituido o no sustituido; el subíndice m es de 0 a 5;R1 es: a) arilo sustituido o no sustituido; o b) heteroarilo sustituido o no sustituido;cada unidad R2 de manera independiente se selecciona del grupo que consiste de: a) hidrógeno, b) -(CH2)jO(CH2)nR8; c) -(CH2)jNR9aR9b; d) -(CH2)jCO2R10; e) -(CH2)jOCO2R10 f) -(CH2)jCON(R10)2; g) -(CH2)jOCON(R10)2; h) dos unidades R2 se pueden unir entre sí para formar una unidad carbonilo; i) y mezclas de los mismos;R8, R9a, R9b y R10 son independientemente hidrógeno, alquilo C1-C4 y mezclas de los mismos; R9a y R9b se pueden unir entre sí y formar un anillo carbocíclico o heterocíclico que tiene de 3 a 7 átomos; dos unidades R10 se pueden unir entre sí y formar a anillo carbocíclico o heterocíclico que tiene de 3 a 7 átomos; el subíndice j tiene un valor de 0 a 5, el subíndice n tiene un valor de 0 a 5;Z es O, S, NR11 o NOR11; R11 es hidrógeno o alquilo C1-C4.
CO04021424A 2001-09-20 2004-03-09 6,7-dihidro-5h-pirazol[1,2-a]pirazol-1-onas que controlan citosinas inflamatorias CO5560589A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32362501P 2001-09-20 2001-09-20

Publications (1)

Publication Number Publication Date
CO5560589A2 true CO5560589A2 (es) 2005-09-30

Family

ID=23259997

Family Applications (3)

Application Number Title Priority Date Filing Date
CO04021424A CO5560589A2 (es) 2001-09-20 2004-03-09 6,7-dihidro-5h-pirazol[1,2-a]pirazol-1-onas que controlan citosinas inflamatorias
CO04021425A CO5560590A2 (es) 2001-09-20 2004-03-09 Compuestos que inhiben la liberacion de citosinas inflamatorias
CO04023010A CO5560579A2 (es) 2001-09-20 2004-03-12 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas espirociclicas que controlan la citosinas inflamatorias

Family Applications After (2)

Application Number Title Priority Date Filing Date
CO04021425A CO5560590A2 (es) 2001-09-20 2004-03-09 Compuestos que inhiben la liberacion de citosinas inflamatorias
CO04023010A CO5560579A2 (es) 2001-09-20 2004-03-12 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas espirociclicas que controlan la citosinas inflamatorias

Country Status (33)

Country Link
US (2) US6566357B1 (es)
EP (3) EP1427732B1 (es)
JP (3) JP2005504082A (es)
KR (4) KR20040035837A (es)
CN (3) CN1249066C (es)
AR (3) AR037502A1 (es)
AT (3) ATE287887T1 (es)
AU (2) AU2002327690B2 (es)
BR (3) BR0212716A (es)
CA (3) CA2461073A1 (es)
CO (3) CO5560589A2 (es)
CY (1) CY1106398T1 (es)
CZ (3) CZ2004361A3 (es)
DE (3) DE60218704T2 (es)
DK (2) DK1427732T3 (es)
EG (2) EG24413A (es)
ES (3) ES2282459T3 (es)
HK (2) HK1071366A1 (es)
HU (3) HUP0500752A2 (es)
IL (3) IL160682A0 (es)
MA (3) MA27066A1 (es)
MX (3) MXPA04002570A (es)
MY (2) MY129329A (es)
NO (2) NO20041594L (es)
NZ (3) NZ531123A (es)
PE (3) PE20030446A1 (es)
PL (3) PL370351A1 (es)
PT (3) PT1427728E (es)
RU (3) RU2278864C2 (es)
SA (1) SA03230529B1 (es)
SK (3) SK1502004A3 (es)
WO (3) WO2003024970A1 (es)
ZA (3) ZA200401260B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849627B2 (en) 2001-09-20 2005-02-01 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7087615B2 (en) 2001-09-20 2006-08-08 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7473695B2 (en) 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US6677337B2 (en) * 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
CA2497007A1 (en) * 2002-09-09 2004-03-18 Amgen Inc. 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivatives s tnf-alpha and interleukin lowering agents for the treatment of inflammations
WO2004087696A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7482356B2 (en) * 2003-11-10 2009-01-27 The Procter & Gamble Company Bicyclic pyrazolone cytokine inhibitors
MY144307A (en) * 2006-04-18 2011-08-29 Abbott Lab Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
PL2432767T3 (pl) * 2009-05-19 2013-11-29 Dow Agrosciences Llc Związki i sposoby zwalczania grzybów
CN107636366B (zh) 2015-06-15 2021-03-12 卡明斯公司 燃烧室弹性装置
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN107033090B (zh) * 2017-05-16 2019-05-07 无锡捷化医药科技有限公司 一种1,2,3,4-四氢噌啉的制备方法
RU2721684C1 (ru) * 2019-09-06 2020-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты
WO2023076133A1 (en) * 2021-10-27 2023-05-04 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054291A (es) * 1963-02-26
GB1124982A (en) * 1965-02-09 1968-08-21 Lepetit Spa Diazabicyclo octanes and derivatives thereof
CH529153A (fr) 1969-10-27 1972-10-15 Lepetit Spa Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones
US5358924A (en) * 1991-03-21 1994-10-25 Bayer Aktiengesellschaft 3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use
PT1481970E (pt) * 1999-09-07 2006-07-31 Syngenta Participations Ag Novos herbicidas
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Also Published As

Publication number Publication date
CZ2004358A3 (cs) 2004-07-14
DK1427728T3 (da) 2007-07-09
AR037237A1 (es) 2004-11-03
HUP0402500A2 (hu) 2005-03-29
PT1427732E (pt) 2006-12-29
HUP0402500A3 (en) 2008-10-28
ATE332901T1 (de) 2006-08-15
MA27066A1 (fr) 2004-12-20
AU2002334641B2 (en) 2007-03-29
PE20030446A1 (es) 2003-07-21
BR0212905A (pt) 2004-10-13
BR0212673A (pt) 2004-08-24
NZ531063A (en) 2007-08-31
ZA200401403B (en) 2004-08-30
CA2461073A1 (en) 2003-03-27
DE60213108T2 (de) 2007-02-08
EP1427727A1 (en) 2004-06-16
ZA200401260B (en) 2004-08-30
CN1555375A (zh) 2004-12-15
PE20030474A1 (es) 2003-07-22
CA2461071A1 (en) 2003-03-27
CN1556811A (zh) 2004-12-22
MA27064A1 (fr) 2004-12-20
PL370362A1 (en) 2005-05-16
DE60218704D1 (de) 2007-04-19
CA2461072A1 (en) 2003-03-27
ATE287887T1 (de) 2005-02-15
NZ531122A (en) 2005-09-30
DE60202782T2 (de) 2006-01-19
WO2003024971A1 (en) 2003-03-27
DE60213108D1 (de) 2006-08-24
IL160741A0 (en) 2004-08-31
MY129069A (en) 2007-03-30
CN1249066C (zh) 2006-04-05
PL370415A1 (en) 2005-05-30
KR100623879B1 (ko) 2006-09-19
NO20041594L (no) 2004-06-21
DE60202782D1 (de) 2005-03-03
SK1492004A3 (en) 2004-11-03
US20030105084A1 (en) 2003-06-05
ES2282459T3 (es) 2007-10-16
HK1071565A1 (en) 2005-07-22
JP2005504081A (ja) 2005-02-10
AR037145A1 (es) 2004-10-27
AU2002327690B2 (en) 2006-07-20
CO5560590A2 (es) 2005-09-30
SK1502004A3 (en) 2004-09-08
KR20040035837A (ko) 2004-04-29
KR100656126B1 (ko) 2006-12-12
EP1427727B1 (en) 2005-01-26
ES2237691T3 (es) 2005-08-01
RU2272040C2 (ru) 2006-03-20
US6566357B1 (en) 2003-05-20
KR20040035835A (ko) 2004-04-29
CY1106398T1 (el) 2011-10-12
HK1071366A1 (en) 2005-07-15
RU2299885C2 (ru) 2007-05-27
PE20030430A1 (es) 2003-06-24
CN1555379A (zh) 2004-12-15
PT1427728E (pt) 2007-05-31
HUP0402378A2 (hu) 2005-02-28
NO20041605L (no) 2004-06-21
EP1427732B1 (en) 2006-07-12
RU2004111803A (ru) 2005-10-10
MXPA04002574A (es) 2004-06-18
US6821971B2 (en) 2004-11-23
CN1250551C (zh) 2006-04-12
PL370351A1 (en) 2005-05-16
ATE356126T1 (de) 2007-03-15
MXPA04002570A (es) 2004-05-31
JP2005504083A (ja) 2005-02-10
IL160682A0 (en) 2004-08-31
DK1427732T3 (da) 2006-10-30
EP1427728A1 (en) 2004-06-16
MXPA04002569A (es) 2004-05-31
CZ2004361A3 (cs) 2004-07-14
RU2004111806A (ru) 2005-03-27
RU2004111805A (ru) 2005-04-10
EP1427732A1 (en) 2004-06-16
BR0212716A (pt) 2004-08-03
HUP0500752A2 (en) 2006-01-30
EP1427728B1 (en) 2007-03-07
IL160742A0 (en) 2004-08-31
EG24413A (en) 2009-05-25
CO5560579A2 (es) 2005-09-30
ES2268154T3 (es) 2007-03-16
MY129329A (en) 2007-03-30
PT1427727E (pt) 2005-06-30
MA27065A1 (fr) 2004-12-20
KR20040035836A (ko) 2004-04-29
JP2005504082A (ja) 2005-02-10
NZ531123A (en) 2006-08-31
HUP0402378A3 (en) 2008-10-28
SA03230529B1 (ar) 2008-06-21
WO2003024970A1 (en) 2003-03-27
CZ2004345A3 (cs) 2004-06-16
DE60218704T2 (de) 2007-11-08
EG24363A (en) 2009-03-04
RU2278864C2 (ru) 2006-06-27
KR20060036125A (ko) 2006-04-27
WO2003024973A1 (en) 2003-03-27
SK1482004A3 (en) 2004-08-03
CN1257905C (zh) 2006-05-31
AR037502A1 (es) 2004-11-17
ZA200401402B (en) 2004-08-27

Similar Documents

Publication Publication Date Title
CO5560589A2 (es) 6,7-dihidro-5h-pirazol[1,2-a]pirazol-1-onas que controlan citosinas inflamatorias
DE69127690T2 (de) Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
SV2002000356A (es) Nuevos derivados de piperazina ref. pc10770aixn/bb
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
ES2193921T3 (es) Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
EA200100757A1 (ru) Хинолинкарбоксамиды в качестве противовирусных агентов
ATE495162T1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
CO5320600A1 (es) Agentes antibacterianos de 3-aminoquinazolin-2,4-dionas
SV2002000195A (es) Compuestos farmaceuticamente activos ref. pcs10342 afae/bb
HN2002000028A (es) Pirimidinas inhibidoras de metaloproteinasas
DE60225671D1 (de) Pharmazeutisch wirksame piperidinderivate
BR0107770A (pt) Derivados de 3-fenóxi-1-fenil acetileno e seu uso como herbicidas
TR200200099T2 (tr) Th2 farklılaşma inhibitörleri
AR070801A1 (es) Derivados pirimidin -piridina
DK1399436T3 (da) Oxytocinagonister
CO5271666A1 (es) Derivados de pirimidina
IT1146726B (it) Derivati della 2 ossoazetidina loro produzione ed impiego
AR044175A1 (es) Compuestos de cefemo
BRPI0415285A (pt) derivados de aminoalcanol
AR024219A1 (es) COMPUESTOS DE QUINOLONAS 2-(NH- U O-SUSTITUIDAS) UTILES COMO INHIBIDORES DE LA METIONIL t-RNA SINTETASA (MRS) COMPOSICIONES FARMACEUTICAS FORMULADAS CONDICHOS COMPUESTOS; PROCEDIMIENTO PARA SU PREPARACION Y USO DE DICHOS COMPUESTOS PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIONES BACTER
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FC Application refused